Status:
ACTIVE_NOT_RECRUITING
CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer
Lead Sponsor:
The Cleveland Clinic
Conditions:
Thyroid Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Radioactive iodine (RAI) is a radioisotope used to ablate thyroid gland remnant after thyroidectomy in patients diagnosed with differentiated thyroid carcinoma (DTC). A whole body scan (WBS) is perfor...
Detailed Description
Radioactive iodine (RAI) is a radioisotope used to ablate thyroid gland remnant after thyroidectomy in patients diagnosed with differentiated thyroid carcinoma (DTC). A whole body scan (WBS) is perfor...
Eligibility Criteria
Inclusion
- Female patients with diagnosis of differentiated thyroid carcinoma who have had thyroidectomy performed previously
- Patients able to understand and sign informed consent for imaging
- Patients already scheduled to undergo radioactive iodine whole body scanning (RAI WBS)
Exclusion
- Males
- Patients with a history of breast cancer
- Patients with a known history of hyperprolactinemia
- Patients receiving medications known to raise serum prolactin
Key Trial Info
Start Date :
July 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04495985
Start Date
July 14 2020
End Date
December 1 2025
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195